Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
21:07:52 EDT Sun 06 Jul 2025
Enter Symbol
or Name
USA
CA



Z:BMY - BRISTOL-MYERS SQUIBB CO - http://www.bristolmyers.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
BMY - Z0.146.85·47.250.146.92-0.065-0.17,024.147.21  47.265  46.69563.33  39.35Jul 03Jun 2615 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2025-06-26 22:05U:BMYNews ReleaseU.S. Food and Drug Administration Approves Streamlined Patient Monitoring Requirements and Removal of REMS Programs within Bristol Myers Squibb's Cell Therapy Labels
2025-06-17 16:16U:BMYNews ReleaseBristol Myers Squibb Announces Dividend
2025-06-16 06:59U:BMYNews ReleaseBristol Myers Squibb Presents First Data from the Marginal Zone Lymphoma Cohort of the Transcend FL Trial Demonstrating Deep and Durable Responses with Breyanzi (lisocabtagene maraleucel)
2025-06-12 06:59U:BMYNews ReleaseBristol Myers Squibb Presents Data Across Targeted Protein Degradation Research Including CELMoD(TM) Agents and BCL6 Ligand-Directed Degrader at EHA 2025
2025-06-12 06:45U:BMYNews ReleaseBristol Myers Squibb to Report Results for Second Quarter 2025 on July 31, 2025
2025-06-11 06:59U:BMYNews ReleaseBristol Myers Squibb Presents Late-Breaking Data from Pivotal Phase 3 POETYK PsA-1 Trial Demonstrating Superiority of Sotyktu (deucravacitinib) Compared with Placebo in Adults with Psoriatic Arthritis
2025-06-10 17:55U:BMYNews ReleasePhilochem AG Announces the Licensing of Worldwide Rights to OncoACP3, a novel Radiopharmaceutical Therapeutic and Diagnostic Agent targeting Prostate Cancer, to RayzeBio, a Bristol-Myers Squibb Company, for a potential value of up to $1.35bn plus royaltie
2025-06-06 09:45U:BMYNews ReleaseMarkey Researchers Awarded $6.8 Million To Help Others Replicate Kentucky's Lung Cancer Screening Success
2025-06-02 06:45U:BMYNews ReleaseBioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
2025-05-28 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
2025-05-28 06:55U:BMYNews ReleaseBristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo(TM) (nivolumab) Across Multiple Solid Tumor Indications
2025-05-22 17:05U:BMYNews ReleaseBristol Myers Squibb to Present Data at ASCO(TM) 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
2025-05-21 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
2025-05-16 06:59U:BMYNews ReleaseBristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo(TM) (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression >=1%
2025-05-07 09:47U:BMYNews ReleaseImproving Access to Care by Strengthening Local Health System Capacity
2025-05-06 06:59U:BMYNews ReleaseBristol Myers Squibb Appoints Cari Gallman as Executive Vice President, General Counsel and Chief Policy Officer
2025-04-24 06:59U:BMYNews ReleaseBristol Myers Squibb Reports First Quarter Financial Results for 2025
2025-04-22 16:15U:BMYNews ReleaseBristol Myers Squibb Announces Topline Results from Phase 3 ARISE Trial Evaluating Cobenfy (xanomeline and trospium chloride) as an Adjunctive Treatment to Atypical Antipsychotics in Adults with Schizophrenia
2025-04-17 20:21U:BMYNews ReleaseU.S. Food and Drug Administration Updates CAMZYOS(TM) (mavacamten) Label to Reduce Echocardiography Monitoring Requirements and Contraindications
2025-04-14 16:15U:BMYNews ReleaseBristol Myers Squibb Provides Update on Phase 3 ODYSSEY-HCM Trial